BlackRock
SYRS

BlackRock’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

BlackRock’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-277,253
Closed -$63.7K – 5537
2024
Q4 		$63.7K Buy
277,253
+15,674
+6% +$18.8K ﹤0.01% 4891
2024
Q3 		$562K Buy
261,579
+2,390
+0.9% +$8.58K ﹤0.01% 4298
2024
Q2 		$1.34M Buy
259,189
+2,148
+0.8% +$11.3K ﹤0.01% 4091
2024
Q1 		$1.38M Buy
257,041
+10,097
+4% +$69.8K ﹤0.01% 4112
2023
Q4 		$1.92M Buy
246,944
+1,199
+0.5% +$4.11K ﹤0.01% 4052
2023
Q3 		$971K Buy
245,745
+34,681
+16% +$130K ﹤0.01% 4251
2023
Q2 		$665K Buy
211,064
+22,910
+12% +$73.6K ﹤0.01% 4404
2023
Q1 		$502K Sell
188,154
-19,565
-9% -$75.8K ﹤0.01% 4528
2022
Q4 		$746K Sell
207,719
-37,514
-15% -$163K ﹤0.01% 4506
2022
Q3 		$1.58M Buy
245,233
+92,802
+61% +$754K ﹤0.01% 4300
2022
Q2 		$1.47M Sell
152,431
-264,583
-63% -$2.48M ﹤0.01% 4379
2022
Q1 		$4.96M Sell
417,014
-6,213
-1% -$111K ﹤0.01% 3965
2021
Q4 		$13.8M Sell
423,227
-12,140
-3% -$492K ﹤0.01% 3485
2021
Q3 		$19.5M Sell
435,367
-10,969
-2% -$535K ﹤0.01% 3295
2021
Q2 		$24.3M Buy
446,336
+29,540
+7% +$1.75M ﹤0.01% 3183
2021
Q1 		$31.2M Buy
416,796
+84,240
+25% +$8.75M ﹤0.01% 2926
2020
Q4 		$36.1M Buy
332,556
+1,569
+0.5% +$143K ﹤0.01% 2679
2020
Q3 		$29.3M Sell
330,987
-1,303
-0.4% -$148K ﹤0.01% 2642
2020
Q2 		$35.4M Buy
332,290
+50,695
+18% +$4.55M ﹤0.01% 2450
2020
Q1 		$16.7M Sell
281,595
-4,746
-2% -$322K ﹤0.01% 2703
2019
Q4 		$19.8M Buy
286,341
+11,865
+4% +$720K ﹤0.01% 2886
2019
Q3 		$28.5M Buy
274,476
+7,760
+3% +$733K ﹤0.01% 2611
2019
Q2 		$24.7M Buy
266,716
+65,674
+33% +$4.57M ﹤0.01% 2733
2019
Q1 		$18.4M Buy
201,042
+2,429
+1% +$169K ﹤0.01% 2784
2018
Q4 		$11.1M Buy
198,613
+37,246
+23% +$2.83M ﹤0.01% 3030
2018
Q3 		$19.2M Buy
161,367
+3,004
+2% +$348K ﹤0.01% 2891
2018
Q2 		$16.2M Buy
158,363
+65,409
+70% +$8.1M ﹤0.01% 2979
2018
Q1 		$12.1M Buy
92,954
+35,459
+62% +$3.88M ﹤0.01% 3039
2017
Q4 		$5.59M Buy
57,495
+515
+0.9% +$69.2K ﹤0.01% 3401
2017
Q3 		$8.39M Buy
56,980
+2,527
+5% +$475K ﹤0.01% 3265
2017
Q2 		$8.76M Buy
54,453
+36,516
+204% +$5.74M ﹤0.01% 3247
2017
Q1 		$2.86M Buy
17,937
+17,912
+71,648% +$2.19M ﹤0.01% 3553
2016
Q4 		$3K Buy
+25
New +$3.5K ﹤0.01% 3610

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BlackRock's SYRS Position: Q1 2025 in Review

BlackRock sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 277,253 shares — an estimated $63.7K sold.

BlackRock first reported a position in SYRS in Q4 2016 and held it in 33 quarters. The position peaked at $36.1M in Q4 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • BlackRock reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • BlackRock sold 277,253 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $63.7K.
  • BlackRock first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 33 quarters.
  • BlackRock's Syros Pharmaceuticals, Inc. Common Stock position peaked at $36.1M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.